BiotechTube
EBViously

EBViously

Munich, Germany· Est.
ebviously.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

EBViously is a private, pre-clinical stage biotech developing a novel VLP vaccine for Epstein-Barr virus. The company is tackling a significant unmet medical need, as EBV is a widespread pathogen with no approved vaccine, linked to acute infectious mononucleosis and serious long-term health risks. Operating from Munich, Germany, the firm is in the early stages of advancing its vaccine candidate, positioning itself in a competitive and high-potential segment of infectious disease prevention. Its success hinges on demonstrating clinical efficacy and navigating the complex development pathway for a first-in-class EBV vaccine.

Infectious DiseaseAutoimmuneOncology

Technology Platform

Next-generation Virus-Like Particle (VLP) vaccine platform engineered to present key Epstein-Barr virus antigens for prophylactic immunization.

Opportunities

The global lack of an approved EBV vaccine represents a massive untapped market, with primary prevention of IM in adolescents as a clear entry point.
The larger, transformative opportunity lies in potentially reducing the incidence of EBV-associated cancers (e.g., lymphomas, nasopharyngeal carcinoma) and autoimmune diseases like multiple sclerosis, which could command premium pricing and widespread public health adoption.

Risk Factors

Major scientific risk exists as achieving protective immunity against EBV has historically been challenging, with previous vaccine candidates showing limited efficacy.
The company also faces significant financial and developmental risks as a pre-revenue, early-stage biotech requiring substantial capital to fund lengthy and complex clinical trials for a first-in-class vaccine.

Competitive Landscape

The competitive landscape includes other biotechs and academic groups pursuing EBV vaccines (e.g., using mRNA, viral vector, or subunit approaches), as well as large pharmaceutical companies with latent interest. Moderna and the NIH have an mRNA-based EBV vaccine in Phase 1 trials. EBViously's differentiation hinges on the potential immunogenic advantages of its VLP platform.

More companies in Germany →